论文部分内容阅读
目的:了解肝细胞癌(hepatocellular carcinoma,HCC)患者的EpsteinBarr病毒(EBV)感染情况,探讨EBV与肝炎病毒有无协同致癌作用。方法:研究组为78例HCC石蜡标本,对照组为26例非癌症肝组织标本。用PCR检测EBVDNA(BamHIW,LMP1)、HBVDNA(S基因、Χ基因),用RTPCR检测HCVRNA和HDVRNA,用免疫组化检测EBV(LMP1)、HBV(HBsAg、HbcAg)和HCV。结果:EBVDNA在HCC组阳性率高于对照组(28.2%vs8.0%),χ2=4.622,P=0.032;HBVDNA在HCC组阳性率高于对照组(56.4%vs23.1%),χ2=8.681,P=0.008;EBV与HBV在HCC组无相关关系,χ2=0.835,P=0.375。HCVRNA、HDVRNA在18例HCC中阳性分别为1和0例。免疫组化测EBV在HCC组阳性率高于对照组(32.1%vs2.5%),χ2=6.02,P=0.012;HBV在HCC组阳性率高于对照组(57.7%vs5.1%),χ2=10.03,P=0.001。结论:EBV在HCC发生中可能起作用,与HBV无明显协同致癌作用;HCV、HDV检出率不高,与EBV关系未能确定。
Objective: To investigate the Epstein Barr virus (EBV) infection in patients with hepatocellular carcinoma (HCC) and to investigate whether EBV and hepatitis B virus have a synergistic carcinogenic effect. Methods: The study group consisted of 78 HCC paraffin specimens and the control group, 26 non-cancerous liver specimens. EBV DNA (BamHIW, LMP1) and HBVDNA (S gene, X gene) were detected by PCR. HCV RNA and HDV RNA were detected by RTPCR and EBV (LMP1), HBV (HBsAg, HbcAg) and HCV were detected by immunohistochemistry. Results: The positive rate of EBVDNA in HCC group was higher than that in control group (28.2% vs 8.0%), χ2 = 4.622, P = 0.032. The positive rate of HBVDNA in HCC group was higher than that in control group (56.4% vs 23.1% 8.681, P = 0.008; EBV and HBV in the HCC group had no correlation, χ2 = 0.835, P = 0.375. HCVRNA, HDVRNA in 18 cases of HCC positive were 1 and 0 cases. The positive rate of EBV in HCC group was significantly higher than that in control group (32.1% vs 2.5%) (χ2 = 6.02, P = 0.012). The positive rate of HBV in HCC group was higher than that in control group (57.7% vs 5.1% χ2 = 10.03, P = 0.001. CONCLUSION: EBV may play a role in the development of HCC and has no obvious synergistic carcinogenic effect with HBV. The detection rate of HCV and HDV is not high, and the relationship with EBV has not been confirmed.